High-potency statins are associated with reduced osteoporosis but increased fracture risk in CKD patients: a multi-center retrospective study
Osteoporosis International · 2026
DOI: 10.1007/s00198-026-08021-6 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Osteoporosis International, 2026. Verfasst von Ping-Hsun Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Osteoporotic Fractures, Renal Insufficiency, Chronic, Osteoporosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Chronic kidney disease patients face increased osteoporosis and fracture risk. High-potency statins were associated with lower osteoporosis incidence but also with higher long-term fracture incidence in this observational study. These findings highlight the need for tailored statin use and proactive fracture monitoring in CKD populations for optimal bone health management. PURPOSE: Chronic kidney disease (CKD) affects approximately 850 million people worldwide and is associated with increased risks of cardiovascular events and fractures. The differential effects of statin potency on bone health in CKD patients remain incompletely understood. METHODS: This retrospective cohort study used the TriNetX US Collaborative Network to identify adults with CKD stages 3 or 4 initiating statin therapy, categorized into high-potency (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) and low-potency groups. After 1:1 propensity score matching, three primary outcomes were evaluated: new osteoporosis diagnosis, anti-osteoporotic medication initiation, and incident fractures, assessed at 3-12 months and beyond 12 months. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox and competing risk regression models. RESULTS: Among 873,180 matched patients, high-potency statins were associated with a 20.0% reduction in osteoporosis diagnosis (HR 0.80; 95% CI 0.78-0.82) and 24.9% fewer anti-osteoporotic medication prescriptions (HR 0.75; 95% CI 0.73-0.78) during 3-12 months, with associations persisting beyond 12 months. Fracture risk did not differ at 3-12 months (HR 0.99; 95% CI 0.96-1.02); but increased beyond 12 months (HR 1.13; 95% CI 1.11-1.15). CONCLUSIONS: High-potency statins are associated with lower osteoporosis diagnosis rates and fewer anti-osteoporotic medication prescriptions in CKD stages 3 and 4. The increased long-term fracture risk may reflect a diagnostic gap wherein lower osteoporosis detection contributes to under-treatment of bone fragility. Prospective randomized controlled trials with bone-specific endpoints are warranted to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Center, for Big Data Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Biomedical Artificial Intelligence Academy, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Orthopedics, College of Medicine, Division of Sports Medicine and Orthopaedic Trauma, Kaohsiung Medical University Hospital, Kaohsiung Medical University, No. 100, Tzyou 1 Road, Kaohsiung, 80708, Taiwan.
Zitieren
APA
Wu, P. H., Lin, Y. T., Chen, J. C., Lin, S. Y., Kao, L. T., Huang, Y. T., Ho, P. S., Chen, C. H., & Lee, T. C. (2026). High-potency statins are associated with reduced osteoporosis but increased fracture risk in CKD patients: a multi-center retrospective study. Osteoporosis International. https://doi.org/10.1007/s00198-026-08021-6
Vancouver
Wu PH, Lin YT, Chen JC, Lin SY, Kao LT, Huang YT, et al. High-potency statins are associated with reduced osteoporosis but increased fracture risk in CKD patients: a multi-center retrospective study. Osteoporosis International. 2026. doi:10.1007/s00198-026-08021-6
BibTeX
@article{Wu2026,
author = {Wu, Ping-Hsun and Lin, Yi-Ting and Chen, Jian-Chih and Lin, Sung-Yen and Kao, Li-Ting and Huang, Yu-Ting and Ho, Pei-Shan and Chen, Chung-Hwan and Lee, Tien-Ching},
title = {High-potency statins are associated with reduced osteoporosis but increased fracture risk in CKD patients: a multi-center retrospective study},
journal = {Osteoporosis International},
year = {2026},
doi = {10.1007/s00198-026-08021-6}
}
EUVIMED